Filing Flows › Veracyte (VCYT) › Q2 2026
Veracyte (VCYT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 31, 2026
Veracyte (VCYT) reported revenue of $150M for the second quarter 2026 (Q2 2026), +15% from a year earlier and +8% from the quarter before. Operating margin was 15.3%, net earnings $25.5M (17.0% of revenue).
Veracyte, Q2 2026: revenue $150M (+16% year over year), operating margin 15.3%, net earnings $25.5M, operating cash flow $45.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $150M | +8% | +15% |
| Gross profit | $109M | +7% | +21% |
| Operating profit | $23.0M | +1% | — |
| Net earnings | $25.5M | -11% | — |
| Operating cash flow | $45.8M | +30% | +36% |
| Free cash flow | $43.0M | +33% | +33% |
What changed
Revenue was $150.3M in Q2 2026, up 15% year over year and up 8% from the previous quarter. Testing revenue was the largest line at 97% of revenue. Testing revenue added $23.4M year over year (up 19%), 116% of the total change. Biopharmaceutical and other revenue declined 81%.
Gross margin was 72.2%, up 3.2 points from Q2 2025. Operating profit was $23.0M, a 15.3% margin (up 19.3 points year over year). Operating expenses fell 10% while revenue rose 15%. The fastest-growing cost line was Research & development (+81%). Net earnings were $25.5M. The effective tax rate was 3.9%.
Operating cash flow was $45.8M (up 36% year over year), 180% of net earnings. Non-cash charges added back $4.8M of depreciation and amortization and $14.1M of share-based compensation. Capital expenditures of $2.9M left free cash flow of $43.0M.
Questions
What was Veracyte's revenue in the second quarter 2026?
Veracyte (VCYT) reported revenue of $150M for the second quarter 2026 (Q2 2026), +15% from a year earlier and +8% from the quarter before.
Was Veracyte profitable in the second quarter 2026?
Operating profit was $23.0M (15.3% of revenue) and net earnings $25.5M.
Source: Veracyte 10-Q on SEC EDGAR.